Ayana Dvir

Low-dose interferon-α accelerates atherosclerosis in an LDL receptor-deficient mouse model

M. Ravid, D. Harats, Z. Levy, 2003 .

Omapatrilat, an Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibitor, Attenuates Early Atherosclerosis in Diabetic and in Nondiabetic Low-Density Lipoprotein Receptor–Deficient Mice

M. Ravid, D. Harats, Z. Levy, 2003, International journal of experimental diabesity research.

Patient-Reported Outcome Measures After Hospitalization During the COVID-19 Pandemic: A Survey Among COVID-19 and Non-COVID-19 Patients

A. Dvir, R. Koren, R. Zaidenstein, 2021, International journal of general medicine.

A novel swine model of ricin-induced acute respiratory distress syndrome

A. Dvir, C. Kronman, B. Cohen, 2017, Disease Models & Mechanisms.

Comparing Cardiac Output Measurements Using a Wearable, Wireless, Noninvasive Photoplethysmography-Based Device to Pulse Contour Cardiac Output in the General ICU: A Brief Report

N. Goldstein, A. Eisenkraft, A. Rapoport, 2022, Critical care explorations.

Rosiglitazone (PPARγ‐agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes–atherosclerosis mouse model

M. Ravid, D. Harats, S. Trestman, 2003, Diabetes, obesity & metabolism.

Low-dose interferon-alpha accelerates atherosclerosis in an LDL receptor-deficient mouse model.

M. Ravid, D. Harats, Z. Levy, 2003, European journal of internal medicine.

Clinical Course and Outcomes of Severe Covid-19: A National Scale Study

P. Singer, M. Amit, S. Sviri, 2020, Journal of clinical medicine.